JP2020508317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508317A5 JP2020508317A5 JP2019545324A JP2019545324A JP2020508317A5 JP 2020508317 A5 JP2020508317 A5 JP 2020508317A5 JP 2019545324 A JP2019545324 A JP 2019545324A JP 2019545324 A JP2019545324 A JP 2019545324A JP 2020508317 A5 JP2020508317 A5 JP 2020508317A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022037781A JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2023190525A JP7656012B2 (ja) | 2017-02-21 | 2023-11-08 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2025044340A JP2025098103A (ja) | 2017-02-21 | 2025-03-19 | 肺癌の処置のための抗ｐｄ－１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461672P | 2017-02-21 | 2017-02-21 | |
| US62/461,672 | 2017-02-21 | ||
| US201762595190P | 2017-12-06 | 2017-12-06 | |
| US62/595,190 | 2017-12-06 | ||
| PCT/US2018/018747 WO2018156494A1 (en) | 2017-02-21 | 2018-02-20 | Anti-pd-1 antibodies for treatment of lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022037781A Division JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508317A JP2020508317A (ja) | 2020-03-19 |
| JP2020508317A5 true JP2020508317A5 (OSRAM) | 2021-07-26 |
| JP7324710B2 JP7324710B2 (ja) | 2023-08-10 |
Family
ID=61628468
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545324A Active JP7324710B2 (ja) | 2017-02-21 | 2018-02-20 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2022037781A Active JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2023190525A Active JP7656012B2 (ja) | 2017-02-21 | 2023-11-08 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2025044340A Pending JP2025098103A (ja) | 2017-02-21 | 2025-03-19 | 肺癌の処置のための抗ｐｄ－１抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022037781A Active JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2023190525A Active JP7656012B2 (ja) | 2017-02-21 | 2023-11-08 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2025044340A Pending JP2025098103A (ja) | 2017-02-21 | 2025-03-19 | 肺癌の処置のための抗ｐｄ－１抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11292842B2 (OSRAM) |
| EP (1) | EP3585812A1 (OSRAM) |
| JP (4) | JP7324710B2 (OSRAM) |
| KR (2) | KR102628557B1 (OSRAM) |
| CN (2) | CN110536905B (OSRAM) |
| AU (2) | AU2018225102B2 (OSRAM) |
| CA (1) | CA3054289A1 (OSRAM) |
| IL (3) | IL321717A (OSRAM) |
| MA (1) | MA47604A (OSRAM) |
| MX (2) | MX2019009772A (OSRAM) |
| WO (1) | WO2018156494A1 (OSRAM) |
| ZA (1) | ZA201905051B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| FI3334763T3 (fi) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Uusia pd-l1-vasta-aineita |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| US11292842B2 (en) * | 2017-02-21 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Anti-PD-1 antibodies for treatment of lung cancer |
| EP3700561A1 (en) * | 2017-10-27 | 2020-09-02 | Statens Serum Institut | A polygene influenza vaccine |
| CN113544144A (zh) | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| PT3880186T (pt) | 2018-11-14 | 2024-05-28 | Regeneron Pharma | Administração intralesional de inibidores de pd-1 para o tratamento do cancro de pele |
| CN113557060A (zh) * | 2019-01-21 | 2021-10-26 | 赛诺菲 | 用于晚期实体瘤癌症的治疗性rna |
| SG11202108089SA (en) * | 2019-02-28 | 2021-08-30 | Regeneron Pharma | Administration of pd-1 inhibitors for treating skin cancer |
| CA3129963A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| EP4074338A4 (en) * | 2019-12-13 | 2024-03-06 | Samsung Bioepis Co., Ltd. | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| ES3014683T3 (en) | 2020-03-13 | 2025-04-24 | Univ Texas | Sequential treatment of cancers using 6-thio-dg and checkpoint inhibitors |
| WO2023185720A1 (zh) * | 2022-03-28 | 2023-10-05 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| EP4598960A1 (en) * | 2022-10-05 | 2025-08-13 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
| WO2025030110A1 (en) * | 2023-08-02 | 2025-02-06 | Sensei Biotherapeutics, Inc. | Cancer therapies targeting vista as monotherapy or in combination with anti-pd1 antibody to treat cancer |
| WO2025159618A1 (ko) | 2024-01-24 | 2025-07-31 | 주식회사 엘지에너지솔루션 | 전극탭 용접장치 및 전극탭 용접방법 |
| WO2025207705A1 (en) | 2024-03-26 | 2025-10-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025213154A1 (en) | 2024-04-05 | 2025-10-09 | Amgen Inc. | Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| WO2009030285A1 (en) | 2007-09-07 | 2009-03-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| HK1207655A1 (en) | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| WO2014018498A1 (en) | 2012-07-23 | 2014-01-30 | Meadwestvaco Calmar, Inc. | Aerosol actuators, devices, and methods of making and using the same |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2015030929A1 (en) | 2013-08-30 | 2015-03-05 | Ebay, Inc. | Keyword bid optimization for text ads |
| US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US20170158776A1 (en) * | 2014-05-15 | 2017-06-08 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| SMT202100116T1 (it) | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| DK3157956T3 (da) | 2014-06-19 | 2020-04-27 | Regeneron Pharma | Ikke-humane dyr med et humaniseret gen med programmeret celledød 1 |
| KR20170101925A (ko) * | 2014-12-02 | 2017-09-06 | 셀진 코포레이션 | 병용 요법 |
| ES2791950T3 (es) | 2015-02-03 | 2020-11-06 | Ventana Med Syst Inc | Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1) |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| NZ735820A (en) * | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| WO2016183326A1 (en) * | 2015-05-12 | 2016-11-17 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2016191751A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| US11292842B2 (en) * | 2017-02-21 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Anti-PD-1 antibodies for treatment of lung cancer |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2023356866A1 (en) * | 2022-10-03 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
-
2018
- 2018-02-20 US US16/486,688 patent/US11292842B2/en active Active
- 2018-02-20 EP EP18711195.0A patent/EP3585812A1/en active Pending
- 2018-02-20 CN CN201880026252.8A patent/CN110536905B/zh active Active
- 2018-02-20 IL IL321717A patent/IL321717A/en unknown
- 2018-02-20 AU AU2018225102A patent/AU2018225102B2/en active Active
- 2018-02-20 IL IL268479A patent/IL268479B2/en unknown
- 2018-02-20 JP JP2019545324A patent/JP7324710B2/ja active Active
- 2018-02-20 CA CA3054289A patent/CA3054289A1/en active Pending
- 2018-02-20 KR KR1020197027687A patent/KR102628557B1/ko active Active
- 2018-02-20 MA MA047604A patent/MA47604A/fr unknown
- 2018-02-20 WO PCT/US2018/018747 patent/WO2018156494A1/en not_active Ceased
- 2018-02-20 CN CN202311425489.2A patent/CN117442719A/zh active Pending
- 2018-02-20 MX MX2019009772A patent/MX2019009772A/es unknown
- 2018-02-20 KR KR1020247001790A patent/KR20240011262A/ko active Pending
-
2019
- 2019-07-31 ZA ZA2019/05051A patent/ZA201905051B/en unknown
- 2019-08-15 MX MX2024000780A patent/MX2024000780A/es unknown
-
2022
- 2022-02-28 US US17/652,709 patent/US11926668B2/en active Active
- 2022-03-11 JP JP2022037781A patent/JP7384949B2/ja active Active
-
2023
- 2023-11-08 JP JP2023190525A patent/JP7656012B2/ja active Active
- 2023-11-23 IL IL308805A patent/IL308805B2/en unknown
-
2024
- 2024-01-29 US US18/425,027 patent/US20240209090A1/en active Pending
-
2025
- 2025-02-13 AU AU2025201018A patent/AU2025201018A1/en active Pending
- 2025-03-19 JP JP2025044340A patent/JP2025098103A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508317A5 (OSRAM) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP2022078265A5 (OSRAM) | ||
| JP2022050618A5 (OSRAM) | ||
| JP2019515008A5 (OSRAM) | ||
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| JP2016520082A5 (OSRAM) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| WO2017042352A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
| CN108350080A (zh) | 用于癌症的联合疗法 | |
| WO2017205216A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2020232019A5 (OSRAM) | ||
| JPWO2020223702A5 (OSRAM) | ||
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| WO2024026019A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| WO2024041652A1 (en) | Methods of cancer treatment | |
| CN119607196A (zh) | 抗lag-3抗体与抗pd-1抗体的应用 | |
| Hwang et al. | Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review |